Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | METAP1 | P53582 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16404333 | 0.91 | METAP1 (0.61) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL25463096 | 0.87 | MEN1 (0.57) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL17275213 | 0.87 | METAP1 (0.57) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL384799 | 0.87 | METAP1 (0.61) | ATMHTTLMNAABCG2METAP1 | |
| SCHEMBL29593068 | 0.86 | ATM (0.59) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL4847197 | 0.86 | ATM (0.59) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL22360436 | 0.83 | METAP1 (0.50) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL5793174 | 0.83 | CYP1B1 (0.64) | ATMHTTNPC1XBP1RAB9A | |
| SCHEMBL31009730 | 0.83 | ABCG2 (0.58) | CYP1A2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL4840414 | 0.83 | ABCG2 (0.58) | CYP1A2KDM4EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | claimed |
| US-10087148-B2 | Quinazolines as biogenic amine transport modulators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3226868-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160159751-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090299-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071055-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-06-28 | — | — | WO | disclosed |
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087148-B2 | Quinazolines as biogenic amine transport modulators | SLC18A2, SLC6A2, SLC6A3 | ATM 2138/4885HTT 272/4885NPC1 686/4885 |
| US-20160159751-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | ATM 2253/4885HTT 277/4885NPC1 738/4885 |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | ATM 4677/4885HTT 462/4885NPC1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.